Diosynth Biotechnology is a company that offers contract cGMP manufacturing of biopharmaceuticals.
Retavase is used in the treatment of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI.
“The agreement to continue the supply of Retavase is an excellent demonstration of our commitment to cGMP production of commercial biologics. We not only manufacture commercial products but we also apply our process development expertise to projects in clinical development and can carry those projects all the way through regulatory applications for our customers,” said Jacques van Kimmenaede, president of Diosynth Biotechnology.